Welcome to our dedicated page for Greenwich Lifesciences news (Ticker: GLSI), a resource for investors and traders seeking the latest updates and insights on Greenwich Lifesciences stock.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) generates news primarily around the clinical and regulatory progress of GLSI-100, its investigational immunotherapy to prevent breast cancer recurrences, and the Phase III FLAMINGO-01 trial. Company press releases highlight milestones in patient screening and enrollment, preliminary clinical observations, regulatory designations, and trial expansion across the United States and Europe.
Readers following GLSI news can expect updates on FLAMINGO-01, including the number of patients screened, enrollment status in the HLA-A*02 and non-HLA-A*02 arms, and preliminary analyses of recurrence rates, immune responses, and safety. The company has reported that more than 1,000 patients have been screened and that the 250-patient non-HLA-A*02 open label arm is fully enrolled, with early analyses suggesting an approximately 80% reduction in recurrence rate after completion of the primary immunization series. These observations are described by the company as preliminary and subject to change as the trial matures.
News items also cover regulatory developments, such as the U.S. FDA granting Fast Track designation for GLSI-100 in the HLA-A*02 genotype population, and geographic expansion of FLAMINGO-01 into additional European countries, including Ireland, Portugal, Belgium, and Austria, following approvals from European regulators. Corporate strategy communications discuss clinical strategy, financing approaches such as at-the-market offerings, partnering activities, and oversight by the Data Safety Monitoring Board and Steering Committee.
For investors, clinicians, and observers, the GLSI news feed offers a consolidated view of how Greenwich LifeSciences describes the evolution of its lead program, including trial design refinements, interactions with regulators, and key governance decisions disclosed through SEC filings and press releases. Regularly reviewing these updates can help track the company’s reported progress in developing GLSI-100 for HER2-positive breast cancer patients.
Greenwich LifeSciences (Nasdaq: GLSI) announced a second abstract publication at the San Antonio Breast Cancer Symposium (SABCS) regarding the Phase III clinical trial for GP2, an immunotherapy aimed at preventing breast cancer recurrence. The trial seeks FDA conditional marketing approval following an interim analysis. Phase IIb results showed a 0% recurrence rate in HER2/neu 3+ patients post-surgery. The trial will involve 11 injections over three years and targets a potential $5 billion market. CEO Patel emphasized the collaboration with Baylor College of Medicine and the significance of the Phase IIb findings.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced the publication of an abstract at the San Antonio Breast Cancer Symposium, highlighting positive results from its Phase IIb clinical trial for GP2 immunotherapy. This therapy demonstrated a 0% recurrence rate in HER2/neu 3+ patients over five years, surpassing the 89.4% rate of placebo patients. A pivotal Phase III trial will follow. With a potential market for GP2 estimated at $5 billion, the therapy aims to address a significant gap for patients unresponsive to current treatments.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) has been selected to present at the virtual Texas Life Science Forum from November 10-12, 2020. CEO Snehal Patel will present on November 10, from 12:00-12:50 pm EST, discussing the GP2 immunotherapy program aimed at preventing breast cancer recurrences. The event also includes one-on-one meetings and a showcase for investors, emphasizing the company's Phase III clinical trial plans. The Texas Life Science Forum, hosted by Rice Alliance and BioHouston, features over 35 life science companies.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) has announced its selection to present at the 2020 BIO Investor Forum and participate in the BIO-Europe partnering conference. CEO Snehal Patel will discuss the GP2 program, aimed at preventing breast cancer recurrences, and plans for a Phase III clinical trial. The investor presentation will be available on the company's website. The BIO-Europe event aims to connect with pharmaceutical companies for potential licensing of therapeutics. In clinical trials, GP2 showed no recurrences in HER2/neu 3+ patients after five years.
Greenwich LifeSciences (Nasdaq: GLSI) has completed the manufacturing of the GP2 active ingredient for its upcoming Phase III clinical trial aimed at preventing breast cancer recurrences. The drug has met all specifications in compliance with current Good Manufacturing Practice (cGMP) and will soon be reformulated and filled into vials. The company also recently completed its IPO, raising substantial funds that will support this critical trial. GP2, already tested in several trials, showed no recurrences in previous studies of HER2/neu positive patients after treatment.
Greenwich LifeSciences announced the closing of its initial public offering, selling 1,260,870 shares at $5.75 each, totaling $7,250,002 in gross proceeds. The offering includes a 45-day option for the underwriter to purchase an additional 189,130 shares. Trading commenced on Nasdaq under the symbol 'GLSI' on September 25, 2020. The company focuses on developing GP2, an immunotherapy aimed at preventing breast cancer recurrence in patients post-surgery. The Phase IIb trial results showed no recurrences after five years in the treated group, highlighting positive clinical outcomes.